header background

Myomics

Myomics is developing novel therapeutics for improving muscle function by using a patented tissue-engineered muscle-based drug screening technology to quickly discover new drugs for a wide range of disorders. Focused on the discovery and screening of compounds to treat indications such as muscle atrophy in the elderly, muscle wasting in chronic illness such as cancer, and muscular dystrophy disorders, the company currently has discovery programs underway based on its two proprietary technology platforms: tissue-engineered muscle, which can be generated in vitro from human and animal models of normal and diseased muscle; and opto-mechanical systems to monitor the ability of candidate compounds to increase the contractile strength of tissue-engineered muscle.

Myomics currently provides compound screening services for pharmaceutical companies, academic centers, and non-profit foundations, and is working to develop small molecule therapeutics for Duchenne Muscular Dystrophy (DMD), for which there are currently no approved drugs.

 


Myomics

NVCA